Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical Revascularization for non-ST-elevation acute coronary syndrome - The Clopidogrel in Unstable Angina to prevent Recurrent Ischemic Events (CURE) trial

被引:666
作者
Fox, KAA
Mehta, SR
Peters, R
Zhao, F
Lakkis, N
Gersh, BJ
Yusuf, S
机构
[1] Univ Edinburgh, Royal Infirm Edinburgh, Edinburgh, Midlothian, Scotland
[2] McMaster Univ, Div Cardiol, Hamilton, ON, Canada
[3] McMaster Univ, Canadian Cardiovasc Collaborat Project Off, Populat Hlth Res Inst, Hamilton, ON, Canada
[4] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[5] Baylor Hosp, Houston, TX USA
[6] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
关键词
clopidogrel; coronary artery bypass; revascularization; coronary disease;
D O I
10.1161/01.CIR.0000140675.85342.1B
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Antiplatelet therapy and antithrombin therapy have been demonstrated to reduce the risk of cardiac events in patients presenting with acute coronary syndrome, yet all effective therapies also increase the risk of bleeding. Methods and Results-In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events ( CURE) trial, 12 562 patients were randomized to clopidogrel or placebo in addition to aspirin, and the primary outcome was cardiovascular ( CV) death, myocardial infarction (MI), or stroke. The benefits were consistent among those undergoing percutaneous coronary intervention (PCI) [9.6% for clopidogrel, 13.2% for placebo; relative risk (RR), 0.72; 95% CI, 0.57 to 0.90], coronary artery bypass grafting (CABG) surgery (14.5% for clopidogrel 16.2% for placebo; RR, 0.89; 95% CI, 0.71 to 1.11), and medical therapy only (8.1% for clopidogrel, 10.0% for placebo; RR, 0.80; 95% CI, 0.69 to 0.92; test for interaction among strata, 0.53). For CABG during the initial hospitalization ( 530 for placebo, 485 for clopidogrel), the frequency of CV death, MI or stroke before CABG was 4.7% for placebo and 2.9% for clopidogrel (RR, 0.56; 95% CI, 0.29 to 1.08). For the entire study, there was a 1% excess of major bleeding but no significant excess of life-threatening bleeding. Among patients undergoing CABG, the rates of life-threatening bleeding were 5.6% for clopidogrel and 4.2% for placebo (RR, 1.30; 95% CI, 0.91 to 1.95; both nonsignificant). Conclusions-The benefits versus risks of early and long-term clopidogrel therapy ( freedom from CV death, MI, stroke, or life-threatening bleeding) are similar in those undergoing revascularization ( CABG or PCI) and in the study population as a whole. Overall, the benefits of starting clopidogrel on admission appear to outweigh the risks, even among those who proceed to CABG during the initial hospitalization.
引用
收藏
页码:1202 / 1208
页数:7
相关论文
共 19 条
[1]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[2]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1498
[3]   Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction [J].
Berkowitz, SD ;
Granger, CB ;
Peiper, KS ;
Lee, KL ;
Gore, JM ;
Simoons, M ;
Armstrong, PW ;
Topol, EJ ;
Califf, RM .
CIRCULATION, 1997, 95 (11) :2508-2516
[4]   Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes:: a meta-analysis of all major randomised clinical trials [J].
Boersma, E ;
Harrington, RA ;
Moliterno, DJ ;
White, H ;
Théroux, P ;
Van de Werf, F ;
de Torbal, A ;
Armstrong, PW ;
Wallentin, LC ;
Wilcox, RG ;
Simes, J ;
Califf, RM ;
Topol, EJ ;
Simoons, ML .
LANCET, 2002, 359 (9302) :189-198
[5]   Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. [J].
Cannon, CP ;
Weintraub, WS ;
Demopoulos, LA ;
Vicari, R ;
Frey, MJ ;
Lakkis, N ;
Neumann, FJ ;
Robertson, DH ;
DeLucca, PT ;
DiBattiste, PM ;
Gibson, CM ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1879-1887
[6]   Management of acute coronary syndromes. Variations in practice and outcome [J].
Fox, KAA ;
Goodman, SG ;
Klein, W ;
Brieger, D ;
Steg, PG ;
Dabbous, O ;
Avezum, A .
EUROPEAN HEART JOURNAL, 2002, 23 (15) :1177-1189
[7]   Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial [J].
Fox, KAA ;
Poole-Wilson, PA ;
Henderson, RA ;
Clayton, TC ;
Chamberlain, DA ;
Shaw, TRD ;
Wheatley, DJ ;
Pocock, SJ .
LANCET, 2002, 360 (9335) :743-751
[8]   A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin - The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS) [J].
Hasdai, D ;
Behar, S ;
Wallentin, L ;
Danchin, N ;
Gitt, AK ;
Boersma, E ;
Fioretti, PM ;
Simoons, ML ;
Battler, A .
EUROPEAN HEART JOURNAL, 2002, 23 (15) :1190-1201
[9]   The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting [J].
Hongo, RH ;
Ley, J ;
Dick, SE ;
Yee, RR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (02) :231-237
[10]   Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease [J].
Kong, DF ;
Califf, RM ;
Miller, DP ;
Moliterno, DJ ;
White, HD ;
Harrington, RA ;
Tcheng, JE ;
Lincoff, AM ;
Hasselblad, V ;
Topol, EJ .
CIRCULATION, 1998, 98 (25) :2829-2835